Cleveland Clinic researchers identify urgent need for Alzheimer's drug development
7th July 2014
Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer’s disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.
The paper, “Alzheimer’s Disease Drug Development Pipeline: Few Candidates, Frequent Failures,” was published in the journal Alzheimer’s Research & Therapy.
Read full article at source http://www.worldpharmanews.com/